Paul Moayyedi, BSc, MB ChB, PhD, MPH, FRCP, FRCPC, FACG, AGAF

Professor, Department of Medicine
Director of Clinical Research, Farncombe Family Digestive Health Research Institute
Director, Division of Gastroenterology


Health Services Research in Gastroenterology


Dr. Moayyedi has a strong interest in evidence based medicine. He qualified in Medicine from Bristol University, UK and obtained a PhD in Medicine as well as a Master’s in Public Health from the University of Leeds, UK. He was appointed Director of the Division of Gastroenterology in 2006. He has conducted a number of large randomized controlled trials and epidemiological studies that have evaluated functional and organic disease of the GI tract. He has also published several systematic reviews that have been influential in British, American and Canadian national guidelines. He is the joint Coordinating Editor for the Upper Gastrointestinal and Pancreatic Diseases Cochrane Review Group based at McMaster and is also Co-Editor-in-Chief of the American Journal of Gastroenterology.


Epidemiology, biostatistics, systematic review and meta-analysis, clinical trials, health economics, decision modeling.

Project 1

Title: Aspirin and PPIs to prevent mortality in Barrett’s patients
Funders: Cancer Research UK and AstraZeneca
Role: Deputy Principal Investigator
Duration: 2004-2014

Project 2

Title: Barrett’s esophagus two yearly surveillance vs. no surveillance: a randomized controlled trial to estimate cost-effectiveness (BOSS)
Funders: National NHS R&D HTA program
Role: Principal Investigator
Duration: 2008-2019

Project 3

Title: The Michael J. Howorth GEM Project
Funders: Crohn’s and Colitis Foundation of Canada
Role: GEM Executive Team
Duration: 2007-2013

Project 4

Title: Cohort study of inflammatory bowel disease after acute enteric infection in Walkerton, Ontario.
Funders: Crohn’s and Colitis Foundation of Canada
Role: Co-investigator (Principal Investigator Dr. John Marshall)
Duration: 2005-2008

  1. Ford, AC, Lacy, BE, Harris, LA, Quigley, EM, Moayyedi, P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. Am. J. Gastroenterol. 2018; :. doi: 10.1038/s41395-018-0222-5. PubMed PMID:30177784 .
  2. Black, CJ, Burr, NE, Quigley, EMM, Moayyedi, P, Houghton, LA, Ford, AC et al.. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. Gastroenterology. 2018; :. doi: 10.1053/j.gastro.2018.08.021. PubMed PMID:30144426 .
  3. Steinhart, AH, Panaccione, R, Targownik, L, Bressler, B, Khanna, R, Marshall, JK et al.. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflamm. Bowel Dis. 2018; :. doi: 10.1093/ibd/izy247. PubMed PMID:30099529 .
  4. Jankowski, JAZ, de Caestecker, J, Love, SB, Reilly, G, Watson, P, Sanders, S et al.. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392 (10145):400-408. doi: 10.1016/S0140-6736(18)31388-6. PubMed PMID:30057104 PubMed Central PMC6083438.
  5. Dionne, J, Ford, AC, Yuan, Y, Chey, WD, Lacy, BE, Saito, YA et al.. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018; :. doi: 10.1038/s41395-018-0195-4. PubMed PMID:30046155 .
  6. Moayyedi, P, Veldhuyzen van Zanten, SJO, Hookey, L, Armstrong, D, Jones, N, Leontiadis, GI et al.. Proton pump inhibitors and gastric cancer: association is not causation. Gut. 2018; :. doi: 10.1136/gutjnl-2018-316958. PubMed PMID:30006494 .
  7. Moayyedi, P. Update on Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2018;14 (5):319-322. . PubMed PMID:29991941 PubMed Central PMC6034605.
  8. Ford, AC, Moayyedi, P, Chey, WD, Harris, LA, Lacy, BE, Saito, YA et al.. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018;113 (Suppl 2):1-18. doi: 10.1038/s41395-018-0084-x. PubMed PMID:29950604 .
  9. Turpin, W, Bedrani, L, Espin-Garcia, O, Xu, W, Silverberg, MS, Smith, MI et al.. FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects. Gut Microbes. 2018; :1-12. doi: 10.1080/19490976.2018.1445956. PubMed PMID:29533703 .
  10. Moayyedi, P, Lacy, BE, Andrews, CN, Enns, RA, Howden, CW, Vakil, N et al.. Response to Marlicz et al. Am. J. Gastroenterol. 2018;113 (5):781. doi: 10.1038/s41395-018-0034-7. PubMed PMID:29523865 .
Search PubMed
Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn